Approval · Notice of Compliance 33276 · 2024
ENTRESTO: Notice of Compliance 33276
Issued May 22, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33276
- Date
- May 22, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving production of the intermediate. Addition of a manufacturing site and/or manufacturer involving production of the starting material. Addition of a manufacturing site and/or manufacturer involving production of the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTRESTO | Not yet assigned | — |
Medicinal ingredients
- VALSARTAN 26 MG per TAB
- SACUBITRIL 24 MG per TAB
- VALSARTAN 51 MG per TAB
- SACUBITRIL 49 MG per TAB
- VALSARTAN 103 MG per TAB
- SACUBITRIL 97 MG per TAB